Background: There is increasing interest in testing surfactant preparations for asthma therapy. Previously, Curosurf was demonstrated to increase inflammation in allergic asthmatics. So far, little is known about the immunomodulatory effects of therapeutic surfactants, in particular concerning the interaction of surfactant components with eosinophils as key effector cells of the allergic airway inflammation. The aim of the present study was to determine the effect of different therapeutic surfactants on cellular functions of eosinophils. Methods: Eosinophils were isolated from peripheral blood of atopic volunteers and incubated with the natural animal-derived surfactants Curosurf or Alveofact or the synthetic recombinant human surfactant Venticute at different concentrations for up to 42 h. Results: Curosurf and Venticute modulated the viability of eosinophils. While incubation with Curosurf increased the number of necrotic eosinophils after 1, 20 and 42 h, Venticute increased the number of apoptotic and necrotic cells after 1 h, but there were no differences compared with control cells at later time points. All surfactant preparations increased the levels of eosinophil cationic protein after 20 h and, in addition, Curosurf enhanced eosinophil cationic protein release after 42 h. The supernatant of eosinophils induced chemotaxis against autologous eosinophils, and the presence of Curosurf, but not Alveofact or Venticute, augmented the chemotactic effect. Chemotaxis was partly blocked by inhibition of eotaxin but not by inhibition of leukotrienes or platelet-activating factor. Conclusions: Therapeutic surfactants differ in their effects on eosinophil viability and the accompanying release of inflammatory mediators and chemotactic signals. Proinflammatory effects were most pronounced for the natural surfactant Curosurf.

Keywords:
Allergic asthma, Eosinophil cationic protein, Chemotaxis, Surfactant
1.
Hohlfeld JM: The role of surfactant in asthma. Respir Res 2002;3:4.
2.
Erpenbeck VJ, Hagenberg A, Dulkys Y, Elsner J, Balder R, Krentel H, Discher M, Braun A, Krug N, Hohlfeld JM: Natural porcine surfactant augments airway inflammation after allergen challenge in patients with asthma. Am J Respir Crit Care Med 2004;169:578–586.
3.
Kurashima K, Ogawa H, Ohka T, Fujimura M, Matsuda T, Kobayashi T: A pilot study of surfactant inhalation in the treatment of asthmatic attack. Arerugi 1991;40:160–163.
4.
Oetomo SB, Dorrepaal C, Bos H, Gerritsen J, van der Mark TW, Koeter GH, van Aalderen WM: Surfactant nebulization does not alter airflow obstruction and bronchial responsiveness to histamine in asthmatic children. Am J Respir Crit Care Med 1996;153:1148–1152.
5.
Woerndle S, Bartmann P: The effect of three surfactant preparations on in vitro lymphocyte functions. J Perinat Med 1994;22:119–128.
6.
Kremlev SG, Phelps DS: Effect of SP-A and surfactant lipids on expression of cell surface markers in the THP-1 monocytic cell line. Am J Physiol 1997;272:L1070–L1077.
7.
Baur FM, Brenner B, Goetze-Speer B, Neu S, Speer CP: Natural porcine surfactant (Curosurf) down-regulates mRNA of tumor necrosis factor-alpha (TNF-alpha) and TNF-alpha type II receptor in lipopolysaccharide-stimulated monocytes. Pediatr Res 1998;44:32–36.
8.
Walti H, Polla BS, Bachelet M: Modified natural porcine surfactant inhibits superoxide anions and proinflammatory mediators released by resting and stimulated human monocytes. Pediatr Res 1997;41:114–119.
9.
Tegtmeyer FK, Gortner L, Ludwig A, Brandt E: In vitro modulation of induced neutrophil activation by different surfactant preparations. Eur Respir J 1996;9:752–757.
10.
Suwabe A, Otake K, Yakuwa N, Suzuki H, Ito M, Tomoike H, Saito Y, Takahashi K: Artificial surfactant (surfactant TA) modulates adherence and superoxide production of neutrophils. Am J Respir Crit Care Med 1998;158:1890–1899.
11.
Lamkhioued B, Renzi PM, Abi-Younes S, Garcia-Zepada EA, Allakhverdi Z, Ghaffar O, Rothenberg MD, Luster AD, Hamid Q: Increased expression of eotaxin in bronchoalveolar lavage and airways of asthmatics contributes to the chemotaxis of eosinophils to the site of inflammation. J Immunol 1997;159:4593–4601.
12.
Gleich GJ: Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol 2000;105:651–663.
13.
Rothenberg ME, Hogan SP: The eosinophil. Annu Rev Immunol 2006;24:147–174.
14.
Cheng G, Ueda T, Nakajima H, Nakajima A, Kinjyo S, Motojima S, Fukuda T: Suppressive effects of SP-A on ionomycin-induced IL-8 production and release by eosinophils. Int Arch Allergy Immunol 1998;117(suppl 1): 59–62.
15.
von Bredow C, Hartl D, Schmid K, Schabaz F, Brack E, Reinhardt D, Griese M: Surfactant protein D regulates chemotaxis and degranulation of human eosinophils. Clin Exp Allergy 2006;36:1566–1574.
16.
Wiseman LR, Bryson HM: Porcine-derived lung surfactant. A review of the therapeutic efficacy and clinical tolerability of a natural surfactant preparation (Curosurf) in neonatal respiratory distress syndrome. Drugs 1994;48:386–403.
17.
Bernhard W, Mottaghian J, Gebert A, Rau GA, von Der HARD, Poets CF: Commercial versus native surfactants. Surface activity, molecular components, and the effect of calcium. Am J Respir Crit Care Med 2000;162:1524–1533.
18.
Spragg RG, Lewis JF, Wurst W, Hafner D, Baughman RP, Wewers MD, Marsh JJ: Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am J Respir Crit Care Med 2003;167:1562–1566.
19.
Babu KS, Woodcock DA, Smith SE, Staniforth JN, Holgate ST, Conway JH: Inhaled synthetic surfactant abolishes the early allergen-induced response in asthma. Eur Respir J 2003;21:1046–1049.
20.
Woerly G, Honda K, Loyens M, Papin JP, Auwerx J, Staels B, Capron M, Dombrowicz D: Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation. J Exp Med 2003;198:411–421.
21.
El Shazly A, Masuyama K, Samejima Y, Eura M, Ishikawa T: Modulation of normal human eosinophil chemotaxis in vitro by herbimycin A, erbstatin and pervanadate. Int Arch Allergy Immunol 1998;117(suppl 1):10–13.
22.
Virchow JC Jr, Faehndrich S, Nassenstein C, Bock S, Matthys H, Luttmann W: Effect of a specific cysteinyl leukotriene-receptor 1-antagonist (montelukast) on the transmigration of eosinophils across human umbilical vein endothelial cells. Clin Exp Allergy 2001;31:836–844.
23.
Kurihara K, Wardlaw AJ, Moqbel R, Kay AB: Inhibition of platelet-activating factor (PAF)-induced chemotaxis and PAF binding to human eosinophils and neutrophils by the specific ginkgolide-derived PAF antagonist, BN 52021. J Allergy Clin Immunol 1989;83:83–90.
24.
Ahuja A, Oh N, Chao W, Spragg RG, Smith RM: Inhibition of the human neutrophil respiratory burst by native and synthetic surfactant. Am J Respir Cell Mol Biol 1996;14:496–503.
25.
Uller L, Persson CG, Erjefalt JS: Resolution of airway disease: removal of inflammatory cells through apoptosis, egression or both? Trends Pharmacol Sci 2006;27:461–466.
26.
Simon HU: Eosinophil apoptosis – pathophysiologic and therapeutic implications. Allergy 2000;55:910–915.
27.
Kankaanranta H, Lindsay MA, Giembycz MA, Zhang X, Moilanen E, Barnes PJ: Delayed eosinophil apoptosis in asthma. J Allergy Clin Immunol 2000;106:77–83.
28.
Sedgwick JB, Calhoun WJ, Vrtis RF, Bates ME, McAllister PK, Busse WW: Comparison of airway and blood eosinophil function after in vivo antigen challenge. J Immunol 1992;149:3710–3718.
29.
Uller L, Rydell-Tormanen K, Persson CG, Erjefalt JS: Anti-Fas mAb-induced apoptosis and cytolysis of airway tissue eosinophils aggravates rather than resolves established inflammation. Respir Res 2005;6:90.
30.
Conroy DM, Williams TJ: Eotaxin and the attraction of eosinophils to the asthmatic lung. Respir Res 2001;2:150–156.
31.
Fregonese L, Silvestri M, Sabatini F, Rossi GA: Cysteinyl leukotrienes induce human eosinophil locomotion and adhesion molecule expression via a CysLT1 receptor-mediated mechanism. Clin Exp Allergy 2002;32:745–750.
32.
Kameyoshi Y, Dorschner A, Mallet AI, Christophers E, Schroder JM: Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med 1992;176:587–592.
33.
Clayton RG, Pickford M, Yang F, Hofmann T, Segal R: Delivery and tolerability of lucinactant aerosol in patients with asthma. Proc Am Thorac Soc 2007;175:A487.
34.
Rennard SI, Basset G, Lecossier D, O’Donnell KM, Pinkston P, Martin PG, Crystal RG: Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 1986;60:532–538.
35.
Wilsher ML, Hughes DA, Haslam PL: Immunomodulatory effects of pulmonary surfactant on natural killer cell and antibody-dependent cytotoxicity. Clin Exp Immunol 1988;74:465–470.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.